Eli Lilly acquires small biotech for $1.6 billion to strengthen cancer immunotherapy pipeline

Posted by on May 12, 2018 10:23 pm
Tags:
Categories: Crispr Articles

Source: Eli Lilly acquires small biotech for $1.6 billion to strengthen cancer immunotherapy pipeline

E

li Lilly  is buying into the cancer immunotherapy business.

In a deal announced Thursday, Lilly said it will acquire a small biotech, ARMO Biosciences, for $50 per share, or $1.6 billion. The transaction values ARMO shares at a 68 percent premium to their closing price on Wednesday night. ARMO, of Redwood City, CA, is developing a new type of drug that stimulates the immune system to fight cancer.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

| Learn More

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What’s included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Senior Writer, Biotech

Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street.

Published at Thu, 10 May 2018 13:54:38 +0000

< Immunotherapy Today home